Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women.

Kotlarczyk MP, Lassila HC, O'Neil CK, D'Amico F, Enderby LT, Witt-Enderby PA, Balk JL.

J Pineal Res. 2012 May;52(4):414-26. doi: 10.1111/j.1600-079X.2011.00956.x.

PMID:
22220591
2.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
3.

Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.

Christopoulou GE, Stavropoulou A, Anastassopoulos G, Panteliou SD, Papadaki E, Karamanos NK, Panagiotopoulos E.

J Pharm Biomed Anal. 2006 Jun 7;41(3):891-7.

PMID:
16488571
4.

Vitamin K supplementation does not significantly impact bone mineral density and biochemical markers of bone in pre- and perimenopausal women.

Volpe SL, Leung MM, Giordano H.

Nutr Res. 2008 Sep;28(9):577-82. doi: 10.1016/j.nutres.2008.06.006.

PMID:
19083462
5.
6.

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.

J Bone Miner Res. 2005 Nov;20(11):1905-11.

7.

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.

Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD.

J Bone Miner Res. 2008 Apr;23(4):525-35. Erratum in: J Bone Miner Res. 2008 Jun;23(6):972.

8.

Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.

Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L.

Obstet Gynecol. 2006 Dec;108(6):1402-10.

PMID:
17138773
10.

Efficacy and safety of bazedoxifene in postmenopausal Asian women.

Xu L, Tsai KS, Kim GS, Wu Y, Vincendon P, Chines AA, Constantine GD.

Osteoporos Int. 2011 Feb;22(2):559-65. doi: 10.1007/s00198-010-1259-5.

PMID:
20535607
11.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36.

12.

A randomized double-blind placebo-controlled trial of a Chinese herbal medicine preparation (Jiawei Qing'e Fang) for hot flashes and quality of life in perimenopausal women.

Xia Y, Zhao Y, Ren M, Zhang J, Wang Y, Chang Y, Fu S, Fan G, Zhu Y, Huang Y, Gao X.

Menopause. 2012 Feb;19(2):234-44. doi: 10.1097/gme.0b013e3182273177.

PMID:
22089177
13.

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.

Choi HJ, Im JA, Kim SH.

Maturitas. 2008 Jun 20;60(2):170-6. doi: 10.1016/j.maturitas.2008.05.003.

PMID:
18572334
14.

Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances.

Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC.

Am J Med. 1994 Jun;96(6):521-30.

PMID:
8017450
15.

Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.

Ste-Marie LG, Sod E, Johnson T, Chines A.

Calcif Tissue Int. 2004 Dec;75(6):469-76.

PMID:
15478000
16.

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.

J Bone Miner Res. 1999 Jul;14(7):1182-8.

18.

Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.

Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K; Probone Study Group..

Osteoporos Int. 2002 Dec;13(12):937-47.

PMID:
12459936
20.
Items per page

Supplemental Content

Support Center